The impact of MRI white matter hyperintensities on dementia in parkinson's disease in relation to the homocysteine level and other vascular risk factors

Neurodegenerative Diseases

Volumn 12, Issue 1, 2013, Pages 1-12

  Sławek, Jarosław ^a,b   Roszmann, Anna ^a,b   Robowski, Piotr ^a,b   Dubaniewicz, Mirosława ^a   Sitek, Emilia J ^a,b   Honczarenko, Krystyna ^c   Gorzkowska, Agnieszka ^d   Budrewicz, Sławomir ^e   Mak, Monika ^c   Goła̧b Janowska, Monika ^c   Koziorowska Gawron, Ewa ^e   Droździk, Marek ^c   Kurzawski, Mateusz ^c   Bandurski, Tomasz ^a   Białecka, Monika ^c  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b ST ADALBERT HOSPITAL   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Dementia; Hippocampal atrophy; Homocysteine; Magnetic resonance imaging; Parkinson's disease; Vascular risk factors

Indexed keywords

AMINOTRANSFERASE; CREATININE; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; GLUCOSE; HOMOCYSTEINE; LIPID; THYROTROPIN; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA;

ADULT; AGED; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BASAL GANGLION; BLOOD SAMPLING; BRAIN ATROPHY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIABETES MELLITUS; ERKINJUNNTTI RATING SCALE; FEMALE; HEART ATRIUM FIBRILLATION; HIPPOCAMPUS; HOEHN AND YAHR SCALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; RISK ASSESSMENT; SCHELTENS SCALE; SCHWAB ENGLAND ACTIVITIES OF DAILY LIVING SCALE; SEMI STRUCTURED INTERVIEW; SMOKING; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ANALOG SCALE; WAHLUND RATING SCALE; WHITE MATTER; ACTIVITY OF DAILY LIVING ASSESSMENT; BECK DEPRESSION INVENTORY; DEMENTIA; MINI MENTAL STATE EXAMINATION; NEURORADIOLOGY; RISK FACTOR;

AGED; BASAL GANGLIA; CARDIOVASCULAR DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIPPOCAMPUS; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS; PARKINSON DISEASE; POLAND; RISK FACTORS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84879409145     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000338610     Document Type: Article

References (72)

1. Levy G, Marder K: Prevalence, incidence and the risk factors for dementia in Parkinson's disease; in Bedard MA, Agid YM, Chouinard S, et al (eds): Mental and Behavioural Dysfunction in Movement Disorders. Totowa, Humana Press, 2003, pp 259-270
2. Aarsland D, Andersen K, Larsen JP, et al: Prevalence and characteristics of dementia in Parkinson's disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392
3. Levy G, Schupf N, Tang MX, et al: Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51: 722-729
4. Wermuth L, Knudsen L, Boldsen J: A study of cognitive functions in young Parkinsonian patients. Acta Neurol Scand 1996; 93: 21-24
5. Aarsland D: Dementia in Parkinson's disease; in O'Brien J, McKeith I, Ames D, Chiu E (eds): Dementia with Lewy Bodies and Parkinson's Disease Dementia. London/New York, Taylor & Francis, 2006, pp 221-239
6. Levy G, Tang MX, Cote LJ, et al: Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 2002; 17: 250-257
7. Haugarvoll K, Aarsland D, Wentzel-Larsen T, et al: The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 2005; 112: 386-390
8. Sławek J, Wieczorek D, Derejko M, Dubaniewicz M, et al: The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neurochir Pol 2008; 42: 505-512
9. Sławek J, Wieczorek D, Derejko M, Dubaniewicz M, et al: Vascular risk factors do not contribute to motor and cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 73-74
10. Burton EJ, McKeith IG, Burn DJ, Firbank MJ, et al: Progression of white matter hyperintensities in Alzheimer's disease, dementia with Lewy bodies and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 2006; 14: 842-849
11. Rodriguez-Oroz MC, Lage PM, Sanchez- Mut J, Lamet I, Pagonabarraga J, et al: Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging and genetic study. Mov Disord 2009; 24: 1437-1444
12. Beyer MK, Aarsland D, Greve OJ, Larsen JP: Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006; 21: 223-229
13. Lee SJ, Kim JS, Yoo JY, Song IU, Kim BS, Jung SL, Yang DW, Kim YI, Jeong DS, Lee KS: Influence of white matter hyperintensities on the cognition of patients with Parkinson's disease. Alzheimer Dis Assoc Disord 2010; 24: 227-233
14. Wolf DS, Gearing M, Snowdon DA: Progression of regional neuropathology in Alzheimer's disease and normal elderly: findings from the Nun Study. Alzheimer Dis Assoc Disord 1999; 13: 226-231
15. Prins ND, Den Heijer T, Hofman A, et al: Homocysteine and cognitive function in the elderly: the Rotterdam scan study. Neurology 2002; 59: 1375-1380
16. Białecka M, Robowski P, Honczarenko K, et al: Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. Neurol Neurochir Pol 2009; 43: 272-278
17. Müller T: Possible treatment concepts for the levodopa-related hyperhomocysteinemia. Cardiovascular Psychiatry Neurol 2009; 2009: 969752
18. Hughes AJ, Daniel SE, Blankson SE, Lees AL: A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148
19. Folstein MF, Folstein SE, McHugh PR: Minimental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
20. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561- 571
21. Mungas D, Marshall S, Weldon W, Haan M, et al: Age and education correction of Mini- Mental State Examination for English and Spanish speaking elderly. Neurology 1996; 46: 700-706
22. Brzezinski J, Gaul M, Hornowska E, Jaworowska A, Machowski A, Zakrzewska M: Skala Inteligencji dla Dorosłych Wechslera. WAIS-R(PL) - podrȩcznik. Warsaw, Pracownia Testów Psychologicznych, 2004
23. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment. New York, Oxford University Press, 2004
24. Kadzielawa D, Mroziak J, Bolewska A, Osiejuk E: Halstead-Reitan Neuropsychological Battery. Manual. Warsaw, Psychological Test Laboratory of the Polish Psychological Association, 1990.
25. Jaworowska A: Wisconsin Card Sorting Test (WCST) - Manual. Warsaw, Laboratory of Psychological Tests, 2002
26. Emre M, Aarsland D, Brown P, et al: Clinical diagnostic criteria in Parkinson's disease associated with dementia. Mov Disord 2007; 12: 1689-1707
27. Wahlund LO, Barkhof F, Fazekas F, et al: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318-1322
28. Erkinjuntti T, Gao F, Lee DH, et al: Lack of difference in brain hyperintensities between patients with early Alzheimer's disease and control subjects. Arch Neurol 1994; 51: 260- 268
29. Scheltens Ph, Leys D, Barkhof F, et al: Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal aging: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972
30. Hughes TA, Ross HF, Musa S, Bhattacherje S, et al: A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54: 1596- 1602
31. Mayeux R, Chen J, Mirabello E, Marder K, et al: An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990; 40: 1513-1517
32. Pantoni L, Garcia JH: Pathogenesis of leukoaraiosis. Stroke 1997; 28: 652-659
33. Young VG, Halliday GM, Krill JJ: Neuropathologic correlates of white matter hyperintensities. Neurology 2008; 71: 804-811
34. Piccini P, Pavese N, Canapicchi R, et al: White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch Neurol 1995; 52: 191-194
35. Ozer F, Meral H, Hanoglu L, et al: Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006; 28: 853-858
36. O'Suilleabhain PE, Sung V, Hernandez C, et al: Elevated plasma homocysteine level in patients with Parkinson's disease: motor, affective and cognitive associations. Arch Neurol 2004; 61: 865-868
37. Hassin-Baer S, Cohen O, Vakil E, et al: Plasma homocysteine levels and Parkinson's disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006; 29: 305-311
38. Zoccolella S, Aquila C, Abruzzese G, et al: Hyperhomocysteinemia in levodopa-treated Parkinson's disease dementia. Mov Disord 2009; 24: 1028-1033
39. Religa D, Czyzewski K, Styczynska M, et al: Hyperhomocysteinemia and methylenetetetrahydrofolate reductase polymorphisms in patients with Parkinson's disease. Neurosci Lett 2006; 404: 56-60
40. Zoccolella S, Lamberti P, Iliceto G, et al: Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005; 43: 1107-1110
41. Smith AD, Smith SM, de Jager CA, et al: Homocysteine- lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010; 5: 1-10
42. Lamberti P, Zoccolella S, Armenise E, et al: Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005; 12: 365-368
43. Müller T, Kuhn W: Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 2006; 62: 447-450
44. Isobe C, Murata T, Sato C, Terayama Y: Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer disease and Parkinson's disease. Life Sci 2005; 77: 1836-1843
45. Isobe C, Abe T, Terayama Y: L-dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease. J Clin Neurosci 2010; 17: 717- 721
46. Irizarry MC, Gurol ME, Raju S, et al: Association of homocysteine with plasma amyloid protein in aging and neurodegenerative disease. Neurology 2005; 65: 1402-1408
47. Rektor I, Goldemund D, Sheardova K, et al: Vascular pathology in patients with idiopathic Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 24-29
48. Nakaso K, Yasui K, Kowa H, et al: Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine and MTHFR genotype. J Neurol Sci 2003; 207: 19-23
49. Zhang C, Cai Y, Adachi MT, et al: Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001; 276: 35867-35874
50. Cook JW, Taylor LM, Orloff SL, et al: Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 2002; 38: 293-300
51. Gattellaro G, Minati L, Grisoli M, et al: White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. Am J Neuroradiol 2009; 30: 1222- 1226
52. Dalaker TO, Larsen JP, Dwyer MG, et al: White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage 2009; 47: 2083-2089
53. Murray ME, Senjem ML, Petersen RC, et al: Functional impact of white matter hyperintensities in cognitively normal elderly. Arch Neurol 2010; 67: 1379-1385
54. Levin KE, Katzen HL: Early cognitive changes and nondementing behavioural abnormalities in Parkinson's disease. Adv Neurol 2005; 96: 84-94
55. Papapetropoulos S, Villar JM, Mash DC: Is ischemic cerebrovascular disease a risk factor for dementia in patients with Parkinson's disease? Acta Neurol Scand 2006; 113: 353- 354
56. Ghebremedhin E, Rosenberger A, Rüb U, et al: Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J Neuropathol Exp Neurol 2010; 69: 442-448
57. Miyake I, Tanaka K, Fukushima W: Casecontrol study of the risk of Parkinson's disease in relation to hypertension, hypercholesterolemia and diabetes mellitus in Japan. J Neurol Sci 2010; 293: 82-86
58. Korten A, Lodder J, Vreeling F, et al: Stroke and idiopathic Parkinson's disease: does shortage of dopamine offer protection against stroke? Mov Disord 2001; 16: 119-123
59. Nataraj A, Rajput AH: Parkinson's disease, stroke and related epidemiology. Mov Disord 2005; 20: 1476-1480
60. Jellinger KA: Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol 2003; 105: 415- 419
61. Scigliano G, Ronchetti G, Girotti F, Mussicco M: Sympathetic modulation by levodopa reduces vascular risk factors for Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 138-143
62. Bouchard TP, Malykhin N, Martin WR, et al: Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008; 29: 1027-1039
63. Ibaretxe-Bilbao N, Tolosa E, Junque C, Marti MJ: MRI and cognitive impairment in Parkinson's disease. Mov Disord 2009; 24(suppl 2):S748-S753
64. Müller T, Renger K, Kuhn W: Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004; 61: 657-660
65. Lee E-S Y, Chen H, Soliman KFA, et al: Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005; 26: 361-371
66. den Heijer T, Vermeer SE, Clarke R, et al: Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003; 126: 170- 175
67. Blundell G, Jones BG, Rose FA, et al: Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996; 122: 163-172
68. Petersen RC: Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007; 27: 22-31
69. Dubois B, Burn D, Goetz C, Aarsland D, et al: Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314-2324
70. Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, et al: Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006; 66: 1941-1943
71. Miller JW, Selhub J, Nadeau MR, et al: Effects of L-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003; 60: 1125-1129
72. Müller T, Muhlack S: Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 688-689. Technology